Alzheimer's Research & Therapy

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
		Review Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease Todd E Golde, Wolfgang J Streit, Paramita Chakrabarty Alzheimer's Research & Therapy 2013, 5:24 (21 May 2013) Abstract \| Full text \| PDF \| Editor’s summary Golde and colleagues review the function of innate immune signalling in Alzheimer's disease (AD) following recent studies showing variants of TREM2, a triggering receptor on myeloid cells, is significantly associated with AD risk.
		Commentary Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013) Abstract \| Full text \| PDF \| PubMed
		Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, David Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
		Review Advances in blood-based protein biomarkers for Alzheimer's disease Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
		Review Modeling Alzheimer's disease with non-transgenic rat models Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
		Review Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
		Review 5-HT₆receptors and Alzheimer's disease María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
		Research Neuroprotective effects of D-Ala²GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
		Research Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
		Review DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
		Letter Plasma tau levels in Alzheimer's disease Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013) Abstract \| Full text \| PDF \| PubMed
		Research The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
		Debate Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
		Review Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
		Review Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
		Research Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
		Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.
		Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
		Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
		Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
		Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
		Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
		Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
		Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
		Commentary Assessment of psychiatric changes in C9ORF72 frontotemporal dementia Michael Hornberger Alzheimer's Research & Therapy 2012, 4:49 (24 December 2012) Abstract \| Full text \| PDF \| PubMed

	All
		Review Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease Todd E Golde, Wolfgang J Streit, Paramita Chakrabarty Alzheimer's Research & Therapy 2013, 5:24 (21 May 2013) Abstract \| Full text \| PDF \| Editor’s summary Golde and colleagues review the function of innate immune signalling in Alzheimer's disease (AD) following recent studies showing variants of TREM2, a triggering receptor on myeloid cells, is significantly associated with AD risk.
		Commentary Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013) Abstract \| Full text \| PDF \| PubMed
		Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, David Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
		Review Advances in blood-based protein biomarkers for Alzheimer's disease Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
		Review Modeling Alzheimer's disease with non-transgenic rat models Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
		Review Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
		Review 5-HT₆receptors and Alzheimer's disease María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
		Research Neuroprotective effects of D-Ala²GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
		Research Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
		Review DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
		Letter Plasma tau levels in Alzheimer's disease Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013) Abstract \| Full text \| PDF \| PubMed
		Research The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
		Debate Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
		Review Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
		Review Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
		Research Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
		Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.
		Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
		Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
		Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
		Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
		Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
		Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
		Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
		Commentary Assessment of psychiatric changes in C9ORF72 frontotemporal dementia Michael Hornberger Alzheimer's Research & Therapy 2012, 4:49 (24 December 2012) Abstract \| Full text \| PDF \| PubMed